Your browser doesn't support javascript.
loading
Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor.
Cottereau, Anne Ségolène; Bricaire, Léopoldine; Arrondeau, Jennifer; Dechmi, Amina; Montravers, Françoise; Coriat, Romain; Clerc, Jerome; Groussin, Lionel; Tenenbaum, Florence.
Afiliação
  • Cottereau AS; Department of Nuclear Medicine, Cochin Hospital, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France. annesegolene.cottereau@aphp.fr.
  • Bricaire L; René Descartes University, Paris, France. annesegolene.cottereau@aphp.fr.
  • Arrondeau J; René Descartes University, Paris, France.
  • Dechmi A; Department of Endocrinology, Cochin Hospital, AP-HP, Paris, France.
  • Montravers F; René Descartes University, Paris, France.
  • Coriat R; Department of Medical Oncology, Cochin Hospital, AP-HP, Paris, France.
  • Clerc J; Department of Nuclear Medicine, Cochin Hospital, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.
  • Groussin L; René Descartes University, Paris, France.
  • Tenenbaum F; Department of Nuclear Medicine, Tenon Hospital, AP-HP, Paris, France.
Invest New Drugs ; 38(4): 1196-1199, 2020 08.
Article em En | MEDLINE | ID: mdl-31650444
Thymic neuro endocrine tumor (tNET) are extremely rare malignancies with poor prognosis, requiring investigation of novel therapeutic approaches. 177Lu-DOTATATE is a successful systemic treatment modality in patients with metastatic gastroenteropancreatic but it role in tNET is not yet well established. Here we report a case of a 39-year-old man with refractory bone marrow infiltration of a tNET, treated by 4 cycles of peptide receptor radionuclide therapy (PRRT) with 177Lu DOTATATE. Since the first cycle, clinical symptoms were substantially decreased, without any severe subacute haematological toxicity. Three months after the end of PRRT, both 68Ga-DOTATOC and 18F-FDG PET confirmed a partial response, already suggested by 177Lu-DOTATATE treatment scan with a significant decrease of the bone marrow uptake between the first and fourth cycle. This report highlights that PRRT could be an effective therapeutic option for advanced bone metastatic disease tNET, with the significant benefit of alleviation of bone pain and radiologic response, without severe or irreversible haematotoxicity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Neoplasias do Timo / Octreotida / Receptores de Peptídeos / Tumores Neuroendócrinos / Neoplasias da Medula Óssea / Compostos Radiofarmacêuticos Tipo de estudo: Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Invest New Drugs Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Neoplasias do Timo / Octreotida / Receptores de Peptídeos / Tumores Neuroendócrinos / Neoplasias da Medula Óssea / Compostos Radiofarmacêuticos Tipo de estudo: Prognostic_studies Limite: Adult / Humans / Male Idioma: En Revista: Invest New Drugs Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França País de publicação: Estados Unidos